Report Overview
About IV Iron Drugs
Iron is one of the most important minerals in the human body. One of the major components of hemoglobin, iron helps the blood carry oxygen. Iron deficiency can affect the production of hemoglobin and cause anemia. This condition is known as iron deficiency anemia.
Technavio’s analysts forecast the global IV iron drugs market to grow at a CAGR of 10.46% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global IV iron drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of IV iron drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global IV Iron Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Allergan
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Galenica
• Pharmacosmos
Other prominent vendors
• Nippon Shinyaku
• NOXXON Pharma
• Rockwell Medical
• Sanofi
• Wanbang Biopharmaceutical
Market driver
• Growing demand for non-dextran intravenous iron drugs
• For a full, detailed list, view our report
Market challenge
• Presence of substitutes coupled with growing research activities for new alternatives
• For a full, detailed list, view our report
Market trend
• Increase in favorable guidelines from healthcare organizations
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Find more reports on related topics - https://www.spendedge.com/
Table Of Contents
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Key market highlights
PART 05: An overview of iron deficiency
PART 06: Pipeline landscape
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Market segmentation by product type
• Ferric carboxymaltose
• Sucrose
• Dextran
• Others
PART 09: Geographical segmentation
• Intravenous iron drugs market in Americas
• Intravenous iron drugs market in EMEA
• Intravenous iron drugs market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments
PART 12: Market trends
• Increase in favorable guidelines from healthcare organizations
• Increasing strategies of vendors to expand reach of intravenous iron drugs
• Growing focus on emerging economies
PART 13: Vendor landscape
• Competitive scenario
PART 14: Key vendor analysis
• Allergan
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Galenica
• Pharmacosmos
• Other prominent vendors
PART 15: Appendix
• List of abbreviation
List of Exhibits
Exhibit 01: Pipeline landscape
Exhibit 02: Global intravenous iron drugs market
Exhibit 03: Annual shipment sales growth of Ferinject/Injectafer in key countries in 2015
Exhibit 04: Global intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 05: Global intravenous iron drugs market: Opportunity analysis
Exhibit 06: Five forces analysis
Exhibit 07: Market segmentation by product type 2016
Exhibit 08: Ferric carboxymaltose-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 09: Global sucrose-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 10: Global dextran-based intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 11: Global other intravenous iron drugs market 2016-2021 ($ millions)
Exhibit 12: Global intravenous iron drugs market by geography 2016 and 2021
Exhibit 13: Global intravenous iron drugs market by geography: Revenue 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: Intravenous iron drugs market in the Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: Intravenous iron drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: Intravenous iron drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Impact of drivers
Exhibit 21: Cost comparison of key drugs per week 2015 ($)
Exhibit 22: Cost comparison of key drugs per treatment 2015 ($)
Exhibit 23: Impact of challenges
Exhibit 24: Competitive structure analysis of global intravenous iron drugs market 2016
Exhibit 25: Market share analysis 2016
Exhibit 26: Competitive analysis of global intravenous iron drugs market
Exhibit 27: Strategic success factors of companies in global intravenous iron drugs market
Exhibit 28: Allergan: Strength assessment
Exhibit 29: Allergan: Strategy assessment
Exhibit 30: Allergan: Opportunity assessment
Exhibit 31: AMAG Pharmaceuticals: Key highlights
Exhibit 32: AMAG Pharmaceuticals: Strength assessment
Exhibit 33: AMAG Pharmaceuticals: Strategy assessment
Exhibit 34: AMAG Pharmaceuticals: Opportunity assessment
Exhibit 35: AMAG Pharmaceuticals: YoY revenue and growth rate of Feraheme ($ millions)
Exhibit 36: Daiichi Sankyo: Key highlights
Exhibit 37: Daiichi Sankyo: Strength assessment
Exhibit 38: Daiichi Sankyo: Strategy assessment
Exhibit 39: Daiichi Sankyo: Opportunity assessment
Exhibit 40: Daiichi Sankyo: YoY revenue and growth rate of Injectafer 2013-2015 ($ millions)
Exhibit 41: Daiichi Sankyo: YoY revenue and growth rate of Venofer 2013-2015 ($ millions)
Exhibit 42: Galenica: Key highlights
Exhibit 43: Galenica: Strength assessment
Exhibit 44: Galenica: Strategy assessment
Exhibit 45: Galenica: Opportunity assessment
Exhibit 46: Galenica: YoY revenue and growth rate of Ferinject 2013-2015 ($ millions)
Exhibit 47: Galenica: YoY revenue and growth rate of Venofer 2013-2015 ($ millions)
Exhibit 48: Pharmacosmos: Key highlights
Exhibit 49: Pharmacosmos: Strength assessment
Exhibit 50: Pharmacosmos: Strategy assessment
Exhibit 51: Pharmacosmos: Opportunity assessment